Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 6/20 | 0.47 |
| ▸ | ADRA2C | P18825 | 4/20 | 0.47 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.43 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.43 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5731688 | 0.90 | ADRA2A (0.47) | ADRA2AADRA2CADRA2BADRA1AADRA1D | |
| SCHEMBL5731772 | 0.87 | ADRA2C (0.43) | ADRA2AADRA2CADRA2BADRA1AADRA1D | |
| SCHEMBL5730525 | 0.87 | ADRA1A (0.53) | ADRA2AADRA2CADRA2BADRA1AADRA1D | |
| SCHEMBL5730494 | 0.84 | TAAR1 (0.46) | ADRA2AADRA2CADRA2BADRA1AADRA1D | |
| SCHEMBL5730470 | 0.83 | ADRA1A (0.39) | ADRA2AADRA2CADRA2BADRA1AADRA1D | |
| SCHEMBL5729356 | 0.82 | ADRA1A (0.44) | ADRA2AADRA2CADRA1AADRA1DADRA1B | |
| SCHEMBL5731220 | 0.78 | ADRA1A (0.47) | ADRA2AADRA2CADRA2BADRA1AADRA1D | |
| SCHEMBL5730273 | 0.78 | ADRA2A (0.55) | ADRA2AADRA2CADRA2BADRA1AADRA1D | |
| Hydrochloric Acid SCHEMBL5730034 | 0.77 | ADRA2A (0.57) | ADRA2AADRA2CADRA2BADRA1AADRA1D | |
| SCHEMBL27597596 | 0.76 | ADRA1A (0.43) | ADRA2AADRA2CADRA1AADRA1DADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100378095-C | Substituted indoles as alpha-1 agonists | HOFFMANN LA ROCHE (CH) | 2008-04-02 | — | — | CN | disclosed |
| EP-1501826-B1 | SUBSTITUTED INDOLES AS ALPHA-1 AGONISTS | HOFFMANN LA ROCHE (CH) | 2006-09-27 | — | — | EP | disclosed |
| CN-1628113-A | Substituted indoles as alpha-1 agonists | HOFFMANN LA ROCHE (CH) | 2005-06-15 | — | — | CN | disclosed |
| US-6852726-B2 | Substituted indoles as alpha-1 agonists | SYNTEX LLC (US) | 2005-02-08 | — | — | US | disclosed |
| EP-1501826-A2 | SUBSTITUTED INDOLES AS ALPHA-1 AGONISTS | F. Hoffman-la Roche AG (CH) | 2005-02-02 | — | — | EP | disclosed |
| US-20030220319-A1 | Substituted indoles as alpha-1 agonists | SYNTEX (U.S.A.) LLC | 2003-11-27 | — | — | US | disclosed |
| WO-2003064387-A2 | SUBSTITUTED INDOLES AS ALPHA-1 AGONISTS | F. HOFFMAN-LA ROCHE AG (CH) | 2003-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220319-A1 | Substituted indoles as alpha-1 agonists | ADRA1A, ADRB1, ADRA1B | ADRA2A 5/4885ADRA2C 10/4885ADRA2B 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.